AIDMP

Access and Integration Drug Management Programme

Clinical Protocols and Guidelines

HSE Prescribing Guideline for Andexanet Alfa (PDF, 690 KB, 8 pages)

HSE Prescribing Protocol for Crohn's Disease (PDF, 243 KB, 4 pages)

HSE Prescribing Protocol for Ulcerative Colitis (PDF, 247 KB, 4 pages)

Enzyme Replacement Therapy

HSE Prescribing Protocol for Sebelipase alfa for the Treatment of Lysosomal Acid Lipase Deficiency (PDF, 961 KB, 14 pages)

HSE Guidelines for the Treatment of Fabry Disease (PDF, 1.2 MB, 17 pages)

HSE Guidelines for the Treatment of Battens Disease with Cerliponase (PDF, 359 KB, 8 pages)

HSE Prescribing Guideline for Sapropterin Dihydrochloride (Kuvan®) Treatment (PDF, 898 KB, 11 pages)

HSE Prescribing Protocol for Alglusidase alfa (Myozyme) for Late-Onset Pompe Disease (PDF, 773 KB, 5 pages)

HSE Prescribing Protocol for Elosulfase alfa (Vimizim) for Mucopolysaccharidosis Type IVa (PDF, 741 KB, 6 pages)

HSE Prescribing Protocol for Idursulfase (Elaprase) for Hunter Syndrome (Mucopolysaccharidosis II) (PDF, 293 KB, 6 pages)

Multiple Sclerosis

MS 100ab Alemtuzumab Protocol, Version 4 (PDF, 837 KB, 8 pages)

MS 100ab Alemtuzumab Patient Eligibility Form, Version 6 (PDF, 170 KB, 1 page)

MS 101ab Natalizumab Protocol, Version 5 (PDF, 912 KB, 7 pages)

MS 101ab Natalizumab Patient Eligibility Form, Version 6 (PDF, 227 KB, 1 page)

MS 103ab Ocrelizumab Protocol, Version 2 (PDF, 323 KB, 7 pages)

MS 103ab Ocrelizumab Patient Eligibility Form, Version 2 (PDF, 509 KB, 1 page)

MS 104 Ublituximab Protocol, Version 2 (PDF, 287 KB, 6 pages)

MS 104 Ublituximab Patient Eligibility Form, Version 1 (PDF, 481 KB, 1 page)

Rare Diseases

HSE Guidelines for the Treatment of XLH with Burosumab (PDF, 298 KB, 6 pages)

XLH001 HSE Burosumab Patient Eligibility Form (PDF, 282 KB, 1 page)

HSE Guidelines for the Treatment of Inherited Retinal Dystrophy with Vortigene Neparvovec (PDF, 1.2 MB, 7 pages)

AIDMP Guidelines

HSE Guidance for Biologic and Biosimilar Medicines use in Acute Hospitals (PDF, 772 KB, 9 pages)

HSE Guidelines for Immunoglobulin use in Neurological Conditions (PDF, 1 MB, 11 pages)